Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18157864 | 0.76 | HSD11B1 (0.42) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL19798632 | 0.73 | HSD11B1 (0.42) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL25454360 | 0.73 | HSD11B1 (0.37) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL28067737 | 0.69 | HSD11B1 (0.41) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL8099017 | 0.69 | HSD11B1 (0.44) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL12705446 | 0.69 | EPHX2 (0.35) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL25454364 | 0.69 | HSD11B1 (0.33) | HSD11B1HSD11B2 | |
| SCHEMBL20730932 | 0.68 | CYP17A1 (0.50) | — | |
| SCHEMBL19911078 | 0.68 | HSD11B1 (0.38) | HSD11B1EPHX2HSD11B2 | |
| SCHEMBL20129585 | 0.68 | GRM5 (0.41) | HSD11B1EPHX2HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-8658639-B2 | N-substituted-cyclic amino derivative | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2014-02-25 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| WO-2010150840-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122773-A1 | N-SUBSTITUTED-CYCLIC AMINO DERIVATIVE | REN, AGTR1, AGTR2 | HSD11B1 85/4885EPHX2 2109/4885HSD11B2 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.